Recently, many media in the United States have reported that on the one hand, the total number of cases and growth rate are still amazing, and on the other hand, there is a long queue of people vaccinated in Florida, Tennessee, Texas and other places.
Although the medical system is overloaded, it is difficult to meet the need to rapidly advance vaccination efforts in the United States.
What should I do? Recently, the head of vaccination in the United States proposed to speed up the vaccination process by reducing the dose of vaccination.
In response, the U.S. Food and Drug Administration quickly issued a warning on January 4, which may put public health at “great risk”.
In December 2020, the U.S. Drug Administration approved two applications for the emergency use of the novel coronavirus vaccine, one jointly developed by Pfizer and the German biotechnology company, and the other by Moderna in the United States.
Monsef Slavy, the head of Operation Warp, the U.S. coronavirus vaccine and drug solution program, has said that he plans to complete the vaccination of 20 million people by the end of December 2020.
However, according to the vaccine data on the website of the U.S. Centers for Disease Control and Prevention, as of January 5 this year, the number of people in the United States had completed the first dose of vaccine was only 4.836 million.
The progress of vaccination is far behind expectations. This situation immediately attracted a lot of criticism in the United States.
Slavey mentioned in an interview with the media on January 3 that if the dose of two doses of the vaccine developed by Moderna is halved when inoculating the population between the ages of 18 and 55, it can double the number of vaccinated people on the basis of existing vaccine supplies, and the same immune response to this age group is being compared with Moderna.
And the U.S. Drug Administration held a discussion on this.
According to the New York Times, researchers at the National Institutes of Health and Moderna are analyzing the relevant data to determine whether it can double the number of vaccinated people by halving the dose of Moderna vaccine.
In response, the U.S. Drug Administration pointed out in a statement on January 4, paying attention to relevant discussions and news reports, but the current changes to the dosage and arrangements for COVID-19 vaccination approved by the United States Drug Administration are too hasty and there is not enough reliable evidence to support it, which may expose public health to great risks and undermine the protection of the public from vaccines.
Efforts to get infected with the coronavirus.
Stanley Pearlman, professor of microbiology and immunology at the University of Iowa in the United States, said in an interview with Xinhua News Agency that the current delay in vaccination in the United States is partly due to problems in production and distribution and the high requirements for cold chain transportation of the two approved vaccines.
